VeriStrat® is a clinically validated serum test for advanced non-small cell lung cancer patients that helps physicians determine if a patient should receive treatment with a drug called erlotinib, an epidermal growth factor receptor inhibitor (EGFRI). The test identifies patients who are likely to have good or poor outcomes after treatment with EGFRIs. VeriStrat requires only a simple blood draw and can be performed on all advanced NSCLC patients. In addition, test results are returned in less than 72 hours thus allowing physicians to make quick treatment decisions.
Visit the VeriStrat website.
Biodesix is currently validating the clinical utility of VeriStrat in other solid tumors (colorectal, pancreatic), and with novel targeted therapies.